Quarterly report pursuant to sections 13 or 15(d)

SEGMENTS

v2.4.0.6
SEGMENTS
3 Months Ended
Mar. 31, 2012
Notes to Financial Statements  
SEGMENTS

 

6. SEGMENTS

 

The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  The Company also operates an FDA-licensed source plasma collection facility located in Norcross, Georgia.  The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources.

 

The plasma collection center segment includes the Company’s operation in Georgia.  The research and development segment includes the Company’s plasma development operations in New Jersey.

 

Summarized financial information concerning reportable segments is shown in the following table:

 

Three Months Ended

March 31, 2012

  Plasma Collection Center     Research and Development     Corporate     Consolidated  
                                 
Revenues   $ 4,400     $ ---     $ ---     $ 4,400  
                                 

Loss

from operations

    (457,093 )     (81,820 )     (674,589 )     (1,213,502 )
                                 
Other (income) expense      ---        ---        1,427        1,427  
                                 
Loss before income taxes     (457,093 )     (81,820 )     (676,016 )     (1,214,929 )
                                 
Property plant and equipment, net      781,765          24,724          8,708          815,197  
                                 
Depreciation and amortization expense        40,500          4,200          1,035          45,735  
                                 

 

Three Months Ended

March 31, 2011

                       
                                 
Revenues   $ ---     $ ---     $ ---     $ ----  
                                 

Loss

from operations

    (376,698 )     (852,194 )     (356,751 )     (1,585,643 )
                                 
Other (income) expense      ---        ---        315,498        315,498  
                                 
Loss before income taxes     (376,698 )     (852,194 )     (672,249 )     (1,901,141 )
                                 
Depreciation and amortization expense        49,500          4,400          1,000          54,900  
                                 

 

The “Corporate” column includes general and administrative overhead expenses.  The column for Research and Development expense includes the loss on sale of research and development inventory.

 

Property, plant and equipment, net, included in the “Other” column above includes assets related to corporate and support functions.